Synthesis and Biological Evaluation of Fangchinoline Derivatives as Anti-Inflammatory Agents through Inactivation of Inflammasome
Open Access
Abstract
Twenty eight 7-substitued fangchinoline analogues, of which twenty two were novel, were synthesized and evaluated for their effect to inhibit lipopolysaccharide/nigericin (LPS/NIG)-induced IL-1β release at both cell and protein levels at the concentration of 5 μM. Among them, compound 6 exhibited promising inhibitory potency against IL-β activation with an IC50 value of 3.7 μM. Preliminary mechanism study revealed that 6 might target NLRP3 protein, and then block ASC pyroptosome formation with-NLRP3, rather than acting on the activation of the NLRP3 inflammasome (NF-κB and MAPK pathways) or caspase-1 protein. Our current study supported the potential role of compound 6 against IL-β activation, and provided powerful information for developing fangchinoline derivatives into a novel class of anti-inflammatory agents.Keywords
Funding Information
- National Natural Science Foundation of China (81321004 and 81473248)
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2016-12M-3-009)
This publication has 22 references indexed in Scilit:
- Structural Moieties Required for Cinnamaldehyde-Related Compounds to Inhibit Canonical IL-1β SecretionMolecules, 2018
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Mechanism and Regulation of NLRP3 Inflammasome ActivationTrends in Biochemical Sciences, 2016
- Molecular mechanisms regulating NLRP3 inflammasome activationCellular & Molecular Immunology, 2015
- The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1βmAbs, 2015
- Inflammasomes: mechanism of action, role in disease, and therapeuticsNature Medicine, 2015
- How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1Cytokine, 2014
- Mechanisms and Functions of InflammasomesCell, 2014
- Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritisMolecular Immunology, 2013
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011